Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA ...
Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA ...
Source: pr-inside.com
📰 Interim Data News
Page 2 - Interim Data News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Interim Data. Real-time updates on events, politics, business and more.
Moderna, Inc.: Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia to be Presented at the 2023 ASGCT Annual Meeting
After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase to
Source: finanznachrichten.de
Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting
Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorders Three oral presentations share meaningful
Source: finanznachrichten.de
MUSTANG BIO, INC. Management's Discussion and Analysis of the Results of Operations (form 10-K)
Statements in the following discussion and throughout this report that are not historical in nature are forward-looking statements. You can identify forward-looking statements by the use of words such... | March 30, 2023
Source: marketscreener.com
Additional Data on Lumos OraGrowtH Trials Presented
Oral Presentation Highlighting Data on 15 Subjects from OraGrowtH212 Trial Supportive of Conclusions from Interim Data Analysis Baseline Characteristics...
Source: globenewswire.com
Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
-- Total Revenue of $157.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $120.4 Million for Full Year 2022, Meeting Companys Guidance -- --...
United States Kyongsang Bukto South Korea United Kingdom Richard Paulson Selective Inhibitor Of Nuclear Export
Source: prnewswire.com
Investegate |Oxford BioDynamics Announcements | Oxford BioDynamics: Initial assessment of EpiSwitch assay in ALS trial
Investegate announcements from Oxford BioDynamics, Initial assessment of EpiSwitch assay in ALS trial
Source: investegate.co.uk
AC Immune's Alzheimer's Disease Vaccine-candidate
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development Data presented at CTAD 2022 confirm excellent clinical...
Andrea Pfeifer Genentech Roche Eli Lilly Janssen Pharmaceuticals Inc Janssen Pharmaceutical Companies Of Johnson Janssen Pharmaceuticals
Source: globenewswire.com
Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
– Achieved Second Quarter 2022 Total Revenue of $39.7 Million, Up 76% Versus Second Quarter 2021; XPOVIO® (selinexor) Net Product Revenue of $29.0 Million, a...
United States United Kingdom Kyongsang Bukto South Korea Richard Paulson Selective Inhibitor Of Nuclear Export
Source: prnewswire.com
Renibus Therapeutics Announces Positive Interim Data from RBT-1 Phase 2 Trial
RBT-1 met primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning; positive data supports the potential for RBT-1 to impact clinical outcomes in cardiothoracic surgery patients
Irvine School United States Frank Stonebanks Bhupinder Singh University Of California Irvine School Of Medicine
Source: dicardiology.com